T
Trinity Biotech plc (TRIB)
NMS – Real Time Price. Currency in USD
0.60
-0.01 (-2.04%)
At close: Mar 27, 2026, 4:00 PM EDT
0.59
-0.01 (-1.81%)
After-hours: Mar 27, 2026, 7:06 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
0.60
-0.01 (-2.04%)
At close: Mar 27, 2026, 4:00 PM EDT
0.59
-0.01 (-1.81%)
After-hours: Mar 27, 2026, 7:06 PM EDT
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
| Name | Position |
|---|---|
| Dr. Gary Keating Ph.D. | Chief Technology Officer |
| Dr. James Walsh Ph.D. | Executive Director of Business Development & Executive Director |
| Mr. John Gillard | President, CEO, Company Secretary & Director |
| Mr. Ronan O'Caoimh A.C.A. | Founder, Director & Executive Advisor |
| Ms. Eibhlin Kelly | Chief Information Officer |
| Ms. Jacqueline O'Neill | Director of Operations |
| Paul Murphy | Interim Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 6-K | zk2634617.htm |
| 2026-03-10 | 6-K | zk2634514.htm |
| 2026-01-27 | F-6EF | trinityf6ef.htm |
| 2026-01-15 | F-1 | zk2634215.htm |
| 2025-12-23 | 6-K | zk2534106.htm |
| 2025-12-18 | 6-K | zk2534115.htm |
| 2025-11-21 | 6-K | zk2534053.htm |
| 2025-11-18 | 6-K | zk2534038.htm |
| 2025-10-23 | 6-K | zk2533873.htm |
| 2025-09-30 | 6-K | zk2533833.htm |